- About Us
- Advisory Board
- Editorial
- Contact Us
- Advertise
- Contact MJH LS
- Do Not Sell My Information
- Terms and Conditions
- Privacy
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Neuromuscular
The NeurologyLive neuromuscular disease clinical focus page offers updates and information related to the clinical care and management of individuals with neuromuscular diseases such as amyotrophic lateral sclerosis, Duchenne muscular dystrophy, cerebral palsy, and spinal muscular atrophy, as well as rare diseases. This page consists of news, podcasts, and videos about the latest FDA actions, clinical guideline updates, interviews with physicians, study and clinical trial findings, and more.
Erenumab Outperforms Topiramate in PROs, Atogepant Dose-Dependent With Weight Changes, Vutrisiran FDA-Approved for ATTR Amyloidosis
June 18, 2022
Video
Neurology News Network for the week ending June 18, 2022. [WATCH TIME: 3 minutes]
NeurologyLive® Friday 5 — June 17, 2022
June 17, 2022
Article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 17, 2022.
2022 SMA Research & Clinical Care Meeting: What to Expect
June 14, 2022
Video
Mary Schroth, MD, and Jacqueline Glascock, PhD, of Cure SMA, share their perspectives on the upcoming annual meeting.
Endoplasmic Reticulum and/or Mitochondrial-Dependent Neuronal Degeneration in ALS
June 14, 2022
Article
Given the importance of mitochondrial and endoplasmic reticulum function in ALS, the disruption of intracellular mitochondria-endoplasmic reticulum contacts presents yet another avenue for neuronal degeneration—perhaps the primary point of underlying dysfunction.
FDA Approves Vutrisiran to Treat hATTR Amyloidosis
June 14, 2022
Article
The approval was based on results from the phase 3 HELIOS-A study, which showed that vutrisiran met its primary end point of change in modified Neuropathy Impairment Score + 7 over a 9-month treatment period.
AMX0035 Approved for ALS Treatment in Canada
June 13, 2022
Article
The approval was based on phase 2/3 findings that showed an average score of 2.32 points higher on ALS Functional Rating Scale with AMX0035 compared with placebo.
This Week on NeurologyLive® — June 13, 2022
June 13, 2022
Article
Here's what is coming soon to NeurologyLive®.
NeurologyLive® Brain Games: June 12, 2022
June 12, 2022
Article
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.
NeurologyLive® Friday 5 — June 10, 2022
June 10, 2022
Article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 10, 2022.
FibroGen Completes Enrollment in LELANTOS-2 Trial of Pamrevlumab in Ambulatory DMD
June 09, 2022
Article
The trial is set to read out topline data in the second half of 2023 after completing the target enrollment of 73 patients with Duchenne muscular dystrophy aged 6 to 12 years. The connective tissue growth factor inhibitor has been granted orphan drug, fast track, and rare pediatric disease designations.